Pacritinib citrate - CAS 1228923-42-9

Pacritinib (SB1518) citrate effectively inhibits wild-type JAK2 (IC 50 =23 nM) and the JAK2 V617F mutant (IC 50 =19 nM) . It also targets FLT3 (IC 50 =22 nM) and the FLT3 D835Y mutant (IC 50 =6 nM) . This compound is utilized in the study of acute myeloid leukemia (AML) and myelofibrosis (MF) [1] [2] [3].

JAK, FLT

JAK/STAT signaling, Angiogenesis, Stem Cells, Tyrosine Kinase/Adaptors, Chromatin/Epigenetic

1228923-42-9

C34H40N4O10

664.7

OC(CC(O)(C(O)=O)CC(O)=O)=O.N1(CCCC1)CCOc2c3cc(Nc4nc(c5cc(COC/C=C/COC3)ccc5)ccn4)cc2

-20°C

Ice Packs

Small Compound